There are 3.25 million deaths pa and significant morbidity in the 65 million COPD and 300 million asthma sufferers in the world. The human rhinovirus (HRV) causes ~60% of COPD and asthma exacerbations. Asthmatics are more susceptible to HRV infections, and acute exacerbations are the major cause of asthma morbidity and mortality. The annual cost of COPD in the EU alone is €39 billion with exacerbations responsible for the majority of costs. There is no HRV vaccine available, primarily due to over 150 serotypically distinct strains in circulation. Prokarium is working with London Metropolitan University to develop novel vaccines which are designed to target this highly variable virus.